Results 231 to 240 of about 16,594 (307)

Diagnostic Value of Rapid On‐Site Evaluation Combined With Prostate Biopsy in Prostate Cancer

The Prostate, Volume 86, Issue 5, Page 542-549, April 2026.
ABSTRACT Objective To investigate the application value of Rapid On‐Site Evaluation (ROSE) in prostate biopsy. Methods All consecutive subjects who attended our clinic to underwent magnetic resonance imaging (MRI)‐ultrasound fusion biopsy due to highly suspicious findings on MRI for prostate cancer (PCa) and met the inclusion criteria were enrolled ...
Hong Ma, Anzi Cao, Huiming Hou, Pengjie Wu, Ben Wan, Ming Liu   +5 more
wiley   +1 more source

Percutaneous cystoscopically and fluoroscopically guided sclerotherapy for treatment of renal hematuria in a cat. [PDF]

J Vet Intern Med
Duh A, Skinner SM, Foster JD.
europepmc   +1 more source

Urine‐Based Bladder Cancer Diagnostics: A Local Evaluation of Cxbladder and Review of the ANZ Landscape

Trends in Urology &Men's Health, Volume 17, Issue 2, April 2026.
ABSTRACT The high demand for cystoscopies performed for bladder cancer diagnosis or surveillance imposes a significant burden on regional centres with limited capacity. Cxbladder is a urinary biomarker test that estimates the likelihood of bladder cancer.
Claris Oh, Kim Tien Chah, Kian Lotter, Steven Lun, Manuel Yuhico   +4 more
wiley   +1 more source

Patient‐reported outcomes: active surveillance vs radical therapies in low‐risk prostate cancer

BJU International, Volume 137, Issue 4, Page 716-727, April 2026.
Objective To prospectively evaluate functional patient‐reported outcomes (PROs) in patients with low‐risk prostate cancer (PCa) managed with active surveillance (AS), nerve‐sparing radical prostatectomy (NS‐RP), non‐NS‐RP, or radiotherapy (RT). Patients and Methods This multicentre prospective cohort study used data from the Prostate Cancer Outcomes ...
Mulham Al‐Nader, Claudia Kesch, Osama Mahmoud, Boris A. Hadaschik, Jan Fichtner, Guenther Carl, Günter Feick, Martin Burchardt, Volker Zimmermanns, Lukas Prause, Bülent Polat, Andreas Blana, Marcus Horstmann, Matthias Saar, Petra Miglierini, Kinan Almansur, Lukas Hefermehl, Daniel Porres, Inga Peters, Kristina Wiens, Rein Jüri Palisaar, Alexander Winter, Andreas Neisius, Eva‐Maria Kunzmann, Nina Natascha Harke, Christian Bolenz, Mohamad Hatem Albarghouth, Lukas Manka, Mario Kramer, Ferdinand Luger, Thomas Knoll, Jesco Pfitzenmaier, Marko Brock, Julia Schittko, Jens Peter Sommer, Matthias Reichert, Sebastian Lenart, Philipp Huber, Sameh Hijazi, Anna Calderaro, Thomas Hermanns, Jens Tonhauser, Christoph Kowalski, Nora Tabea Sibert   +43 more
wiley   +1 more source

Endoscopic management of ureteric stenosis and calculi in bilateral incomplete renal duplication: A case study. [PDF]

Biomedicine (Taipei)
Warraich HSA, Younis Z, Warraich J, Warraich K.   +3 more
europepmc   +1 more source

From Dismissal to Partnership: Patient Experiences of Recurrent Urinary Tract Infection Healthcare Informed by the Theoretical Domains Framework and Behaviour Change Theory

Health Expectations, Volume 29, Issue 2, April 2026.
ABSTRACT Background Recurrent urinary tract infection (rUTI) is common, debilitating, and associated with substantial negative impact on quality of life. Despite this, rUTI healthcare is often experienced as fragmented, dismissive, and poorly aligned with patient needs.
Abigail F. Newlands, Melissa L. Kramer, Sarah Snuggs, Katherine A. Finlay   +3 more
wiley   +1 more source

Ongoing evolution of urinary tract disorders in dromedary camels (<i>Camelus dromedarius</i>): a comprehensive illustrated sonographic overview. [PDF]

Front Vet Sci
Tharwat M, Elmoghazy HMM.
europepmc   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

The Diagnostic Accuracy of Reduced-Dose CT of the Kidneys, Ureters, and Bladder in the Evaluation of Renal Colic. [PDF]

Cureus
Haji O, Gronczewska LP, Nunow M, Ali Z, Davidson SA, Manibalan S.   +5 more
europepmc   +1 more source

Expression of Nectin‐4 and Trop‐2 in upper tract urothelial carcinoma: implications for biomarker‐driven antibody‐drug conjugate therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 2, March 2026.
Abstract Recent advancements in antibody‐drug conjugates, including FDA‐approved therapies targeting Nectin‐4 and Trop‐2, have transformed the cancer treatment landscape, including upper tract urothelial carcinoma (UTUC). However, varied treatment effects and drug‐associated adverse effects raise the question of whether patients should be selected ...
Ping Shi, Qingqing Wu, Yong Zhang, Tiane Chen, Joshua I. Warrick, David J. DeGraff, Jay D. Raman, Guoli Chen   +7 more
wiley   +1 more source